Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease

A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease Karl Kieburtz, MD, MPH; Michael P. McDermott, PhD; Tiffini S. Voss, MD; Jody Corey-Bloom, MD, PhD; Lisa M. Deuel, BA; E. Ray Dorsey, MD, MBA; Stewart Factor, DO; Michael D. Geschwind, MD, PhD; Karen Hodgeman, CCRA; Elise Kayson, MS, RNC; Sarah Noonberg, MD, PhD; Michael Pourfar, MD; Karen Rabinowitz, JD; Bernard Ravina, MD, MSCE; Juan Sanchez-Ramos, MD, PhD; Lynn Seely, MD; Francis Walker, MD; Andrew Feigin, MD; and The Dimebon in Subjects With Huntington Disease (DIMOND) Investigators of the Huntington Study Group Objectives: To evaluate the safety and tolerability of and the Alzheimer Disease Assessment Scale–cognitive latrepirdine in Huntington disease (HD) and explore its subscale (ADAS-cog). effects on cognition, behavior, and motor symptoms. Results: Latrepirdine was well tolerated (87% of the Design: Double-blind, randomized, placebo-controlled patients given latrepirdine completed the study vs 82% trial. in the placebo group), and adverse event rates were comparable in the 2 groups (70% in the latrepirdine Setting: Multicenter outpatient trial. group and 80% in the placebo group). Treatment with latrepirdine resulted in improved mean MMSE scores Participants: Ninety-one participants with mild to mod- compared with stable performance http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Loading next page...
 
/lp/american-medical-association/a-randomized-placebo-controlled-trial-of-latrepirdine-in-huntington-rsnsIb64Ie
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/archneurol.2009.334
pmid
20142523
Publisher site
See Article on Publisher Site

Abstract

CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease Karl Kieburtz, MD, MPH; Michael P. McDermott, PhD; Tiffini S. Voss, MD; Jody Corey-Bloom, MD, PhD; Lisa M. Deuel, BA; E. Ray Dorsey, MD, MBA; Stewart Factor, DO; Michael D. Geschwind, MD, PhD; Karen Hodgeman, CCRA; Elise Kayson, MS, RNC; Sarah Noonberg, MD, PhD; Michael Pourfar, MD; Karen Rabinowitz, JD; Bernard Ravina, MD, MSCE; Juan Sanchez-Ramos, MD, PhD; Lynn Seely, MD; Francis Walker, MD; Andrew Feigin, MD; and The Dimebon in Subjects With Huntington Disease (DIMOND) Investigators of the Huntington Study Group Objectives: To evaluate the safety and tolerability of and the Alzheimer Disease Assessment Scale–cognitive latrepirdine in Huntington disease (HD) and explore its subscale (ADAS-cog). effects on cognition, behavior, and motor symptoms. Results: Latrepirdine was well tolerated (87% of the Design: Double-blind, randomized, placebo-controlled patients given latrepirdine completed the study vs 82% trial. in the placebo group), and adverse event rates were comparable in the 2 groups (70% in the latrepirdine Setting: Multicenter outpatient trial. group and 80% in the placebo group). Treatment with latrepirdine resulted in improved mean MMSE scores Participants: Ninety-one participants with mild to mod- compared with stable performance

Journal

JAMA NeurologyAmerican Medical Association

Published: Feb 1, 2010

References